论文部分内容阅读
用我们建立的白血病综合药敏试验方法对58例白血病病人临床治疗疗效进行前瞻性预测,结果单药预测的符合率为87.9％,联合药物预测的符合率为89.7％,体外药物试验敏感程度指标平均药敏积分与体内2个疗程后骨髓白血病细胞下降百分数有非常显著的相关关系,P<0.001。初步分析表明,药敏试验的符合率在急性白血病各类型之间以及初治和复发病人之间没有明显差异。
We established the leukemia comprehensive susceptibility test method in 58 cases of leukemia clinical efficacy of the prospective prediction, the results of single-drug prediction rate was 87.9%, the combined drug prediction rate of 89.7%, in vitro drug sensitivity test indicators There was a significant correlation between the mean drug sensitivity score and the percentages of myeloid leukemia cells after 2 courses of treatment, P <0.001. Preliminary analysis showed that the coincidence rate of susceptibility testing in acute leukemia and between the various types of initial and recurrence patients no significant difference.